Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family members by 50% at concentrations (IC50 's) ranging from 10 to 99 nM and did not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nm). Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nm). Oclacitinib also inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nm. Oclacitinib had minimal effects on cytokines that did not activate the JAK1 enzyme in cells (erythropoietin, granulocyte/macrophage colony-stimulating factor, IL-12, IL-23; IC50 's > 1000 nm). These results demonstrate that oclacitinib is a targeted therapy that selectively inhibits JAK1-dependent cytokines involved in allergy, inflammation, and pruritus and suggests these are the mechanisms by which oclacitinib effectively controls clinical signs associated with allergic skin disease in dogs.https://www.bocsci.com/oclacitinib-cas-1208319-26-9-item-462291.html

BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-informed decisions tailored to your evolving needs for premium chemicals. Our complete suite of CRO services spans the entire molecule development pipeline including contract research for target identification, building blocks, compound synthesis, biochemical and cellular analysis, preclinical animal tests, and clinical studies.

Products:

BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.

Over eight years of successful operation in the pharmaceutical industry has enabled us to possess a full-bodied array of building blocks in numerous pack sizes. BOC Sciences is constantly seeking to expand our product lines by incorporating additional potential drug like molecules.



Services:

BOC Sciences provides a wide range of services to support the pharmaceutical industry through all stages of drug discovery including Custom Synthesis of those chemicals that are not in stock, Isotope Labeling Service, Chiral Synthesis and Resolution, Bioconjugation, PEGylation services, analytical services.

Our capacity to provide pharmaceutical discovery services across the entire spectrum of the drug discovery process has assisted many of our esteemed clients in reaching their R&D goals. We are actively improving our capabilities and capacity through new expansions in BOC Sciences’s global business.



Manufacturing services:

-> Manufacture of raw materials, registered GMP starting materials and intermediates from small scale (1kg) to commercial quantities (1000 kg);
-> Production of APIs to support drug candidate selections;
-> GLP toxicology studies and clinical studies;
-> Development and optimization of environmentally friendly process;
-> Competitive quality and price comparable to commodity chemical suppliers


Our clients



As a leading provider of building blocks, synthetic intermediates, and custom synthesis, BOC Sciences is committed to supplying cost-effective products and services, which are being utilized by our customers worldwide in molecule discovery on a daily basis to promote innovations in various industries.